Loading...

IXHL INCANNEX HEALTHCARE INC US FDA Inspections 8-K Filing

NCNN

XHL

INCANNEX HEALTHCARE INC

(IXHL)

2025 8-K

FDA Fast Track Designation

Shareholder Update

Regained Compliance

Nasdaq Compliance Update

Positive Trial Results

Share Repurchase Program

Product Expansion

At-the-market Offering

Product Expansion

Equity Offerings

Transfer of Listing

Product Expansion

Equity Offerings

Warrant Cancellations

Equity Offerings

Warrant Adjustments

Asset Acquisitions

Financial Statements

Product Expansion

Failure to meet listing sta...

Sales Agreement

Trial Enrollment

Private Placement

Quarterly Results

Management Appointment

Positive Study Results

Annual Meeting Results

Management Change

Management Appointment

Funding Agreement

Financial Results

Equity Financing

Equity Financing

FDA Review Complete

Clinical Trial Completion

Clinical Trial Commencement

FDA Meeting for CannQuit-O

Quarterly Earnings

Management Changes

Clinical Trial Results

FDA Meeting for CannQuit-N

Approval for MDMA and Psilo...

Clinical Trial Commencement

Clinical Trial Completion

Clinical Trial Approval

Endorsement for Psychedelic...

Appointment of New Independ...

Redomiciliation Completion

External Links:

On December 3, 2025, Incannex Healthcare Inc. announced it received U.S. FDA Fast Track designation for its product IHL-42X aimed at treating obstructive sleep apnea. This designation may accelerate the development and review process for the medication, which could positively impact the company’s prospects.

AI Assistant

INCANNEX HEALTHCARE INC

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.